Literature DB >> 15741928

New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease.

William J Sandborn1.   

Abstract

Crohn's disease is a T helper type 1 response immune disease characterized by increased production of interleukin-12 tumor necrosis factor-a (TNF-a), and interferon-g. Clinical trials have demonstrated that inhibition of TNF is effective for the treatment of Crohn's disease. Adverse events reported in patients treated with anti-TNF agents include immunogenicity, acute infusion reactions, delayed hypersensitivity-type reactions, autoimmune diseases including drug-induced lupus and demyelination, and infection. This article reviews new concepts in the treatment of Crohn's disease and ulcerative colitis with a variety of anti-TNF biologic therapies: infliximab, adalimumab, CDP870, CDP571, etanercept, and onercept.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15741928

Source DB:  PubMed          Journal:  Rev Gastroenterol Disord        ISSN： 1533-001X


  11 in total

Review 1.  Practical guidelines for the treatment of inflammatory bowel disease.

Authors:  T Kuhbacher; U R Fölsch
Journal:  World J Gastroenterol       Date:  2007-02-28       Impact factor: 5.742

Review 2.  Disseminated aspergillosis following infliximab therapy in an immunosuppressed patient with Crohn's disease and chronic hepatitis C: a case study and review of the literature.

Authors:  Joel W Alderson; Thomas G Van Dinter; Michael J Opatowsky; Elizabeth C Burton
Journal:  MedGenMed       Date:  2005-09-21

3.  Beneficial effects of Etanercept on experimental necrotizing enterocolitis.

Authors:  Sadık Yurttutan; Ramazan Ozdemir; Fuat Emre Canpolat; Mehmet Yekta Oncel; Hatice Germen Unverdi; Bülent Uysal; Ömer Erdeve; Ugur Dilmen
Journal:  Pediatr Surg Int       Date:  2013-09-27       Impact factor: 1.827

4.  Bacterial meningitis associated with infliximab.

Authors:  Raymond Farah; Svetlana Lisitsin; Moshe Shay
Journal:  Pharm World Sci       Date:  2006-09-27

5.  TNF-alpha and shear stress-induced large artery adaptations.

Authors:  C Keith Ozaki; Zhihua Jiang; Scott A Berceli
Journal:  J Surg Res       Date:  2007-06-15       Impact factor: 2.192

6.  Etanercept clearance during an in vitro model of continuous venovenous hemofiltration.

Authors:  Geoffrey M Fleming; Noha N Salama; Saada K Eid; Kenneth R Cooke; Bruce A Mueller
Journal:  Blood Purif       Date:  2009-09-01       Impact factor: 2.614

Review 7.  Cytokines and the early vein graft: strategies to enhance durability.

Authors:  C Keith Ozaki
Journal:  J Vasc Surg       Date:  2007-06       Impact factor: 4.268

Review 8.  Stem cells as potential therapeutic targets for inflammatory bowel disease.

Authors:  Udai P Singh; Narendra P Singh; Balwan Singh; Manoj K Mishra; Mitzi Nagarkatti; Prakash S Nagarkatti; Shree Ram Singh
Journal:  Front Biosci (Schol Ed)       Date:  2010-06-01

9.  LITAF mediation of increased TNF-α secretion from inflamed colonic lamina propria macrophages.

Authors:  Kristen N Bushell; Susan E Leeman; Earl Gillespie; Adam C Gower; Karen L Reed; Arthur F Stucchi; James M Becker; Salomon Amar
Journal:  PLoS One       Date:  2011-09-30       Impact factor: 3.240

10.  Dynamics of pro-inflammatory and anti-inflammatory cytokine release during acute inflammation in chronic obstructive pulmonary disease: an ex vivo study.

Authors:  Tillie-Louise Hackett; Rebecca Holloway; Stephen T Holgate; Jane A Warner
Journal:  Respir Res       Date:  2008-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.